{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:20:23Z","timestamp":1794378023778,"version":"4.9.0"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"am","delay-in-days":702,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R01DE028351"],"award-info":[{"award-number":["R01DE028351"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R03DE028387"],"award-info":[{"award-number":["R03DE028387"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"EMORY UNIVERSITY","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007258","name":"State University of New York","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010956","name":"State University of New York Upstate Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biomaterials.2022.121876","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T22:04:13Z","timestamp":1666908253000},"page":"121876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications"],"prefix":"10.1016","volume":"291","author":[{"given":"Kun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zapata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5535-1807","authenticated-orcid":false,"given":"Yamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib1","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide-sequence of the iap gene, responsible for alkaline-phosphatase isozyme conversion in escherichia-coli, and identification of the gene-product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-2958.2000.01838.x","article-title":"Biological significance of a family of regularly spaced repeats in the genomes of Archaea, bacteria and mitochondria","volume":"36","author":"Mojica","year":"2000","journal-title":"Mol. Microbiol."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib4","doi-asserted-by":"crossref","DOI":"10.1128\/JB.00580-17","article-title":"History of CRISPR-cas from encounter with a mysterious repeated sequence to genome editing technology","volume":"200","author":"Ishino","year":"2018","journal-title":"J. Bacteriol."},{"issue":"5819","key":"10.1016\/j.biomaterials.2022.121876_bib5","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"issue":"6096","key":"10.1016\/j.biomaterials.2022.121876_bib6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"39","key":"10.1016\/j.biomaterials.2022.121876_bib7","doi-asserted-by":"crossref","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","article-title":"Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria","volume":"109","author":"Gasiunas","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6121","key":"10.1016\/j.biomaterials.2022.121876_bib8","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"6121","key":"10.1016\/j.biomaterials.2022.121876_bib9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2022.121876_bib10","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","article-title":"RNA-programmed genome editing in human cells","volume":"2","author":"Jinek","year":"2013","journal-title":"Elife"},{"key":"10.1016\/j.biomaterials.2022.121876_bib11","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1017\/S0033583519000052","article-title":"Development of CRISPR-Cas systems for genome editing and beyond","volume":"52","author":"Zhang","year":"2019","journal-title":"Q. Rev. Biophys."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro3279","article-title":"Unravelling the structural and mechanistic basis of CRISPR-Cas systems","volume":"12","author":"van der Oost","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro3241","article-title":"CRISPR-Cas systems: beyond adaptive immunity","volume":"12","author":"Westra","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41589-020-00700-7","article-title":"Controlling and enhancing CRISPR systems","volume":"17","author":"Shivram","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nbt.3198","article-title":"Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells","volume":"33","author":"Chu","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib17","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.biomaterials.2022.121876_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2014.08.033","article-title":"Improving the specificity and efficacy of CRISPR\/CAS9 and gRNA through target specific DNA reporter","volume":"189","author":"Zhang","year":"2014","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jbiotec.2016.06.011","article-title":"Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing","volume":"233","author":"Kelley","year":"2016","journal-title":"J. Biotechnol."},{"issue":"6268","key":"10.1016\/j.biomaterials.2022.121876_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","article-title":"Rationally engineered Cas9 nucleases with improved specificity","volume":"351","author":"Slaymaker","year":"2016","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nbt.2909","article-title":"Fusion of catalytically inactive Cas9 to Fokl nuclease improves the specificity of genome modification","volume":"32","author":"Guilinger","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"13","key":"10.1016\/j.biomaterials.2022.121876_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.2174\/1389201019666180209120533","article-title":"New developments in CRISPR technology: improvements in specificity and efficiency","volume":"18","author":"Safari","year":"2017","journal-title":"Curr. Pharmaceut. Biotechnol."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib23","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib24","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/nbt.3659","article-title":"Applications of CRISPR technologies in research and beyond","volume":"34","author":"Barrangou","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"6213","key":"10.1016\/j.biomaterials.2022.121876_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib26","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biomaterials.2022.121876_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/B978-0-12-801185-0.00008-8","article-title":"Genome editing using Cas9 nickases","volume":"546","author":"Trevino","year":"2014","journal-title":"Methods Enzymol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib30","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nmeth.2600","article-title":"RNA-guided gene activation by CRISPR-Cas9-based transcription factors","volume":"10","author":"Perez-Pinera","year":"2013","journal-title":"Nat. Methods"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nmeth.3733","article-title":"Editing the epigenome: technologies for programmable transcription and epigenetic modulation","volume":"13","author":"Thakore","year":"2016","journal-title":"Nat. Methods"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib34","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","article-title":"Base editing: advances and therapeutic opportunities","volume":"19","author":"Porto","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7785","key":"10.1016\/j.biomaterials.2022.121876_bib36","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tibtech.2017.11.006","article-title":"Engineering the delivery system for CRISPR-based genome editing","volume":"36","author":"Glass","year":"2018","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"2018","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1609","article-title":"Strategies for nonviral nanoparticle-based delivery of CRISPR\/Cas9 therapeutics","volume":"12","author":"Chen","year":"2020","journal-title":"Wiley Interdisciplinary Reviews-Nanomedicine And Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tips.2019.11.006","article-title":"Strategies for the CRISPR-based therapeutics","volume":"41","author":"Li","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41587-020-0565-5","article-title":"The delivery challenge: fulfilling the promise of therapeutic genome editing","volume":"38","author":"van Haasteren","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2022.121876_bib43","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","article-title":"In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease","volume":"6","author":"Lau","year":"2017","journal-title":"F1000Research"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/v11010028","article-title":"Viral delivery systems for CRISPR","volume":"11","author":"Xu","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib45","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"issue":"15","key":"10.1016\/j.biomaterials.2022.121876_bib46","doi-asserted-by":"crossref","first-page":"9874","DOI":"10.1021\/acs.chemrev.6b00799","article-title":"CRISPR\/Cas9-Based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery","volume":"117","author":"Wang","year":"2017","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/153303460300200513","article-title":"Viral and non-viral vectors in gene therapy: technology development and clinical trials","volume":"2","author":"Lundstrom","year":"2003","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.biomaterials.2022.121876_bib48","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","article-title":"Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting","volume":"266","author":"Kim","year":"2017","journal-title":"J. Contr. Release"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib50","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1039\/D0NR07622H","article-title":"Exosome-mediated delivery of gene vectors for gene therapy","volume":"13","author":"Duan","year":"2021","journal-title":"Nanoscale"},{"issue":"21","key":"10.1016\/j.biomaterials.2022.121876_bib51","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1021\/acs.accounts.1c00500","article-title":"Developing biodegradable lipid nanoparticles for intracellular mRNA delivery and genome editing","volume":"54","author":"Qiu","year":"2021","journal-title":"Accounts Chem. Res."},{"issue":"18","key":"10.1016\/j.biomaterials.2022.121876_bib52","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1039\/D1BM00537E","article-title":"Harnessing lipid nanoparticles for efficient CRISPR delivery","volume":"9","author":"Yan","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2022.121876_bib53","article-title":"Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR\/Cas9","volume":"65","author":"Ashok","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"20","key":"10.1016\/j.biomaterials.2022.121876_bib54","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1039\/D0TB00207K","article-title":"Lipid and polymer mediated CRISPR\/Cas9 gene editing","volume":"8","author":"Gong","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib56","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery aspects of CRISPR\/cas for in vivo genome editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Accounts Chem. Res."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib57","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1021\/acsnano.6b07600","article-title":"Direct cytosolic delivery of CRISPR\/Cas9-Ribonucleoprotein for efficient gene editing","volume":"11","author":"Mout","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2022.121876_bib58","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.actbio.2020.07.027","article-title":"Engineering of monosized lipid-coated mesoporous silica nanoparticles for CRISPR delivery","volume":"114","author":"Noureddine","year":"2020","journal-title":"Acta Biomater."},{"issue":"32","key":"10.1016\/j.biomaterials.2022.121876_bib59","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1002\/anie.201806941","article-title":"Enhanced cytosolic delivery and release of CRISPR\/cas9 by black phosphorus nanosheets for genome editing","volume":"57","author":"Zhou","year":"2018","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1021\/jacs.7b11754","article-title":"Endosomal escape and delivery of CRISPR\/Cas9 genome editing machinery enabled by nanoscale zeolitic imidazolate framework","volume":"140","author":"Alsaiari","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biomaterials.2022.121876_bib61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2017.09.012","article-title":"Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications","volume":"266","author":"Liu","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121876_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2020.100895","article-title":"Harnessing nanoparticles for the efficient delivery of the CRISPR\/Cas9 system","volume":"34","author":"Rahimi","year":"2020","journal-title":"Nano Today"},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib63","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjugate Chem."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib64","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1039\/C8BM01310A","article-title":"Biomaterials as vectors for the delivery of CRISPR-Cas9","volume":"7","author":"Eoh","year":"2019","journal-title":"Biomater. Sci."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib65","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/ijms17050626","article-title":"In vivo delivery systems for therapeutic genome editing","volume":"17","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib66","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms19092721","article-title":"In vivo genome editing as a therapeutic approach","volume":"19","author":"Ho","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib67","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1021\/acschembio.7b00680","article-title":"The promise and challenge of in vivo delivery for genome therapeutics","volume":"13","author":"Wilson","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib68","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41578-019-0145-9","article-title":"Engineered materials for in vivo delivery of genome-editing machinery","volume":"4","author":"Tong","year":"2019","journal-title":"Nat. Rev. Mater."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib69","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.0c04707","article-title":"Delivery of tissue-targeted scalpels: opportunities and challenges for in vivo CRISPR\/Cas-Based genome editing","volume":"14","author":"Wei","year":"2020","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib70","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biomaterials.2022.121876_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.673286","article-title":"Nanoparticle delivery of CRISPR\/Cas9 for genome editing","volume":"12","author":"Duan","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.biomaterials.2022.121876_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.addr.2020.09.004","article-title":"Non-viral strategies for delivering genome editing enzymes","volume":"168","author":"Li","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2022.121876_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41572-021-00275-0","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib75","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jalz.2015.06.1883","article-title":"Alzheimer's Disease Neuroimaging Initiative: a decade of progress in Alzheimer's disease","volume":"11","author":"Thies","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib76","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamainternmed.2021.4607","article-title":"Approval of aducanumab for alzheimer disease\u2014the FDA's perspective","volume":"181","author":"Dunn","year":"2021","journal-title":"JAMA Intern. Med."},{"issue":"51","key":"10.1016\/j.biomaterials.2022.121876_bib77","doi-asserted-by":"crossref","first-page":"42867","DOI":"10.1074\/jbc.M112.407072","article-title":"BACE1 protein endocytosis and trafficking are differentially regulated by ubiquitination at lysine 501 and the Di-leucine motif in the carboxyl terminus","volume":"287","author":"Kang","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib78","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41593-019-0352-0","article-title":"In vivo neuronal gene editing via CRISPR-Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer's disease","volume":"22","author":"Park","year":"2019","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"issue":"42","key":"10.1016\/j.biomaterials.2022.121876_bib80","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1523\/JNEUROSCI.3183-05.2005","article-title":"Full motor recovery despite striatal neuron loss and formation of irreversible amyloid-like inclusions in a conditional mouse model of Huntington's disease","volume":"25","author":"Diaz-Hernandez","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biomaterials.2022.121876_bib81","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","article-title":"CRISPR-Cas9-Mediated genome editing increases lifespan and improves motor deficits in a huntington's disease mouse model","volume":"17","author":"Ekman","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"16","key":"10.1016\/j.biomaterials.2022.121876_bib82","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib83","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib84","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib85","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/s41551-018-0252-8","article-title":"Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours","volume":"2","author":"Lee","year":"2018","journal-title":"Nat Biomed Eng"},{"issue":"22","key":"10.1016\/j.biomaterials.2022.121876_bib86","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aar3952","article-title":"In vivo genome editing improves motor function and extends survival in a mouse model of ALS","volume":"3","author":"Gaj","year":"2017","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib88","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","article-title":"Treatment of a mouse model of ALS by in vivo base editing","volume":"28","author":"Lim","year":"2020","journal-title":"Mol. Ther."},{"issue":"30","key":"10.1016\/j.biomaterials.2022.121876_bib89","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4429","article-title":"Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection","volume":"6","author":"Ma","year":"2020","journal-title":"Sci. Adv."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib90","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/ar.22579","article-title":"Genetics of hearing and deafness","volume":"295","author":"Angeli","year":"2007","journal-title":"Anatomical record (Hoboken, N.J."},{"issue":"6184","key":"10.1016\/j.biomaterials.2022.121876_bib91","first-page":"596","article-title":"Sound strategies for hearing restoration","volume":"344","author":"G\u00e9l\u00e9oc","year":"2014","journal-title":"Science (American Association for the Advancement of Science)"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib92","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrd4533","article-title":"New treatment options for hearing loss","volume":"14","author":"Muller","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib93","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.neuron.2013.06.019","article-title":"TMC1 and TMC2 are components of the mechanotransduction channel in hair cells of the mammalian inner ear","volume":"79","author":"Pan","year":"2013","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib94","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/ng842","article-title":"Dominant and recessive deafness caused by mutations of a novel gene, TMC1 , required for cochlear hair-cell function","volume":"30","author":"Griffith","year":"2002","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00424-014-1582-3","article-title":"Transmembrane channel-like (TMC) genes are required for auditory and vestibular mechanosensation","volume":"467","author":"Kawashima","year":"2014","journal-title":"Pfl\u00fcgers Archiv"},{"issue":"7687","key":"10.1016\/j.biomaterials.2022.121876_bib96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature25164","article-title":"Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents","volume":"553","author":"Gao","year":"2018","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib97","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41591-019-0500-9","article-title":"Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss","volume":"25","author":"Gyorgy","year":"2019","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015063","article-title":"Visual responses in mice lacking critical components of all known retinal phototransduction cascades","volume":"5","author":"Allen","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/bjophthalmol-2015-306939","article-title":"A novel homozygous truncating GNAT1 mutation implicated in retinal degeneration","volume":"100","author":"Carrigan","year":"2016","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.exer.2009.09.010","article-title":"A nonsense mutation in Gnat1, encoding the alpha subunit of rod transducin, in spontaneous mouse models of retinal dysfunction","volume":"90","author":"Miyamoto","year":"2010","journal-title":"Exp. Eye Res."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib101","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.ymthe.2018.07.012","article-title":"Retained plasticity and substantial recovery of rod-mediated visual acuity at the visual cortex in blind adult mice with retinal dystrophy","volume":"26","author":"Nishiguchi","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib102","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41467-019-14181-3","article-title":"Single AAV-mediated mutation replacement genome editing in limited number of photoreceptors restores vision in mice","volume":"11","author":"Nishiguchi","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib103","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.tig.2008.08.007","article-title":"MMEJ repair of double-strand breaks (director's cut): deleted sequences and alternative endings","volume":"24","author":"McVey","year":"2008","journal-title":"Trends Genet."},{"key":"10.1016\/j.biomaterials.2022.121876_bib104","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nprot.2015.140","article-title":"MMEJ-assisted gene knock-in using TALENs and CRISPR-cas9 with the PITCh systems","volume":"11","author":"Sakuma","year":"2016","journal-title":"Nat. Protoc."},{"issue":"7631","key":"10.1016\/j.biomaterials.2022.121876_bib105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib106","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/cr.2017.57","article-title":"Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors","volume":"27","author":"Zhu","year":"2017","journal-title":"Cell Res."},{"issue":"1\u20132","key":"10.1016\/j.biomaterials.2022.121876_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41434-021-00258-6","article-title":"Restoration of RPGR expression in vivo using CRISPR\/Cas9 gene editing","volume":"29","author":"Gumerson","year":"2022","journal-title":"Gene Ther."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41551-020-00656-y","article-title":"Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice","volume":"5","author":"Ling","year":"2021","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.biomaterials.2022.121876_bib109","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/gr.219089.116","article-title":"Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration","volume":"27","author":"Kim","year":"2017","journal-title":"Genome Res."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib111","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib112","article-title":"Dual supramolecular nanoparticle vectors enable CRISPR\/Cas9-Mediated knockin of retinoschisin 1 gene-A potential nonviral therapeutic solution for X-linked juvenile retinoschisis","volume":"7","author":"Chou","year":"2020","journal-title":"Adv. Sci."},{"key":"10.1016\/j.biomaterials.2022.121876_bib113","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.actbio.2019.10.037","article-title":"Carboxylated nanodiamond-mediated CRISPR-Cas9 delivery of human retinoschisis mutation into human iPSCs and mouse retina","volume":"101","author":"Yang","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biomaterials.2022.121876_bib114","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2021.06.030","article-title":"In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles","volume":"336","author":"Wang","year":"2021","journal-title":"J. Contr. Release"},{"issue":"22","key":"10.1016\/j.biomaterials.2022.121876_bib115","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2007.09.011","article-title":"Universal definition of myocardial infarction","volume":"50","author":"Thygesen","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121327","article-title":"In vivo therapeutic genome editing via CRISPR\/Cas9 magnetoplexes for myocardial infarction","volume":"281","author":"Park","year":"2022","journal-title":"Biomaterials"},{"issue":"7439","key":"10.1016\/j.biomaterials.2022.121876_bib117","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature11919","article-title":"MicroRNA-34a regulates cardiac ageing and function","volume":"495","author":"Boon","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib118","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCRESAHA.118.313369","article-title":"In vivo Ryr2 editing corrects catecholaminergic polymorphic ventricular tachycardia","volume":"123","author":"Pan","year":"2018","journal-title":"Circ. Res."},{"issue":"18","key":"10.1016\/j.biomaterials.2022.121876_bib119","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","article-title":"Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia","volume":"119","author":"Hayashi","year":"2009","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib120","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCRESAHA.117.310083","article-title":"Calcium signaling and cardiac arrhythmias","volume":"120","author":"Landstrom","year":"2017","journal-title":"Circ. Res."},{"issue":"33","key":"10.1016\/j.biomaterials.2022.121876_bib121","doi-asserted-by":"crossref","first-page":"E4895","DOI":"10.1073\/pnas.1605216113","article-title":"Leaky RyR2 channels unleash a brainstem spreading depolarization mechanism of sudden cardiac death","volume":"113","author":"Aiba","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib122","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/1061186X.2020.1818761","article-title":"Therapeutic advances in cardiac targeted drug delivery: from theory to practice","volume":"29","author":"Li","year":"2021","journal-title":"J. Drug Target."},{"key":"10.1016\/j.biomaterials.2022.121876_bib123","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.biopha.2016.12.009","article-title":"Heart targeted nanoliposomal\/nanoparticles drug delivery: an updated review","volume":"86","author":"Cheraghi","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"25 Suppl 2","key":"10.1016\/j.biomaterials.2022.121876_bib124","first-page":"S1","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib126","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib127","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/CIRCRESAHA.115.304351","article-title":"Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing","volume":"115","author":"Ding","year":"2014","journal-title":"Circ. Res."},{"issue":"7546","key":"10.1016\/j.biomaterials.2022.121876_bib128","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"33","key":"10.1016\/j.biomaterials.2022.121876_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201902575","article-title":"Fast and efficient CRISPR\/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles","volume":"31","author":"Liu","year":"2019","journal-title":"Adv. Mater."},{"issue":"36","key":"10.1016\/j.biomaterials.2022.121876_bib131","doi-asserted-by":"crossref","first-page":"12404","DOI":"10.1002\/anie.201903618","article-title":"Triple-targeting delivery of CRISPR\/Cas9 to reduce the risk of cardiovascular diseases","volume":"58","author":"Zhang","year":"2019","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib132","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib133","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nbt.4005","article-title":"Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing","volume":"35","author":"Yin","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib134","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.ymthe.2021.02.020","article-title":"Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9","volume":"29","author":"Wang","year":"2021","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib135","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/ATVBAHA.117.309881","article-title":"In vivo base editing of PCSK9 (proprotein convertase subtilisin\/kexin type 9) as a therapeutic alternative to genome editing","volume":"37","author":"Chadwick","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"34","key":"10.1016\/j.biomaterials.2022.121876_bib136","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc2315","article-title":"Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib137","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng814","article-title":"Angptl3 regulates lipid metabolism in mice","volume":"30","author":"Koishi","year":"2002","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib138","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7555\/JBR.32.20170114","article-title":"Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia","volume":"33","author":"Tarugi","year":"2019","journal-title":"J Biomed Res"},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib139","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.biomaterials.2022.121876_bib140","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biomaterials.2022.121876_bib141","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","article-title":"CRISPR-Cas9-Mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice","volume":"18","author":"Wang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib142","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj6901","article-title":"In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy","volume":"8","author":"Han","year":"2022","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib143","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax5701","article-title":"A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib144","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib145","article-title":"Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib146","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib147","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/hum.2017.225","article-title":"In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency","volume":"29","author":"Song","year":"2018","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib148","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib149","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1021\/acs.chemmater.0c02571","article-title":"Delivery of CRISPR\/Cas9 plasmids by cationic gold nanorods: impact of the aspect ratio on genome editing and treatment of hepatic fibrosis","volume":"33","author":"Chen","year":"2020","journal-title":"Chem. Mater."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib151","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib152","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nbt.3471","article-title":"Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo","volume":"34","author":"Yin","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib153","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12642","article-title":"Reprogramming metabolic pathways in vivo with CRISPR\/Cas9 genome editing to treat hereditary tyrosinaemia","volume":"7","author":"Pankowicz","year":"2016","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib154","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"488","key":"10.1016\/j.biomaterials.2022.121876_bib155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav8375","article-title":"In utero gene editing for monogenic lung disease","volume":"11","author":"Alapati","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib156","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1073\/pnas.101500298","article-title":"Altered stability of pulmonary surfactant in SP-C-deficient mice","volume":"98","author":"Glasser","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib157","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41551-022-00847-9","article-title":"Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver","volume":"6","author":"Sago","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib158","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.3390\/ijms21113903","article-title":"Gene therapy for cystic fibrosis: progress and challenges of genome editing","volume":"21","author":"Maule","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib159","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1566523220666201230100523","article-title":"TGF-beta1-based CRISPR\/Cas9 gene therapy attenuates radiation-induced lung injury","volume":"22","author":"Zhen","year":"2022","journal-title":"Curr. Gene Ther."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib160","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib161","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ymthe.2021.10.023","article-title":"AAV5 delivery of CRISPR-Cas9 supports effective genome editing in mouse lung airway","volume":"30","author":"Liang","year":"2022","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib162","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1566523220666201012145731","article-title":"CRISPR\/Cas9 genome editing tool: a promising tool for therapeutic applications on respiratory diseases","volume":"20","author":"Shaikh","year":"2020","journal-title":"Curr. Gene Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib163","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.addr.2007.11.006","article-title":"Targeted delivery of nanoparticles for the treatment of lung diseases","volume":"60","author":"Azarmi","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib164","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/nano10020183","article-title":"Multifunctional nanocarriers for lung drug delivery","volume":"10","author":"Pontes","year":"2020","journal-title":"Nanomaterials"},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib165","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3390\/jcm5090082","article-title":"Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery","volume":"5","author":"Yhee","year":"2016","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib166","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"issue":"6271","key":"10.1016\/j.biomaterials.2022.121876_bib167","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1016\/j.biomaterials.2022.121876_bib168","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1016\/j.biomaterials.2022.121876_bib169","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2022.121876_bib170","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib171","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.117.310996","article-title":"In vivo genome editing restores dystrophin expression and cardiac function in dystrophic mice","volume":"121","author":"El Refaey","year":"2017","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib172","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib173","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13073-021-00876-0","article-title":"In vivo genome editing in mouse restores dystrophin expression in Duchenne muscular dystrophy patient muscle fibers","volume":"13","author":"Chen","year":"2021","journal-title":"Genome Med."},{"key":"10.1016\/j.biomaterials.2022.121876_bib174","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib175","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib176","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0303-7207(92)90004-P","article-title":"Testosterone and 5\u03b1-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene","volume":"88","author":"Deslypere","year":"1992","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib177","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/jid.2011.274","article-title":"Dihydrotestosterone-inducible IL-6 inhibits elongation of human hair shafts by suppressing matrix cell proliferation and promotes regression of hair follicles in mice","volume":"132","author":"Kwack","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib178","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1172\/JCI116665","article-title":"Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression","volume":"92","author":"Thigpen","year":"1993","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib179","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2013.10.049","article-title":"A randomized, active-and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia","volume":"70","author":"Harcha","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119736","article-title":"Ultrasound-activated particles as CRISPR\/Cas9 delivery system for androgenic alopecia therapy","volume":"232","author":"Ryu","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib181","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib182","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib183","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nm.3467","article-title":"Netrin-1 promotes adipose tissue macrophage retention and insulin resistance in obesity","volume":"20","author":"Ramkhelawon","year":"2014","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib184","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acsnano.7b07874","article-title":"Macrophage-specific in vivo gene editing using cationic lipid-assisted polymeric nanoparticles","volume":"12","author":"Luo","year":"2018","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib185","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1038\/s41467-018-06522-5","article-title":"Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases","volume":"9","author":"Xu","year":"2018","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121876_bib186","article-title":"In vivo editing of macrophages through systemic delivery of CRISPR-cas9-ribonucleoprotein-nanoparticle nanoassemblies","volume":"2","author":"Lee","year":"2019","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib187","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1007\/s12274-018-2150-5","article-title":"Optimized nanoparticle-mediated delivery of CRISPR-Cas9 system for B cell intervention","volume":"11","author":"Li","year":"2018","journal-title":"Nano Res."},{"key":"10.1016\/j.biomaterials.2022.121876_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119302","article-title":"In situ repurposing of dendritic cells with CRISPR\/Cas9-based nanomedicine to induce transplant tolerance","volume":"217","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib189","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.onc.1208273","article-title":"Polo-like kinases and oncogenesis: polo-like kinases","volume":"24","author":"Eckerdt","year":"2005","journal-title":"Oncogene"},{"issue":"19","key":"10.1016\/j.biomaterials.2022.121876_bib190","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1073\/pnas.1712963115","article-title":"Nonviral gene editing via CRISPR\/Cas9 delivery by membrane-disruptive and endosomolytic helical polypeptide","volume":"115","author":"Wang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib191","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201700175","article-title":"Genome editing for cancer therapy: delivery of Cas9 protein\/sgRNA plasmid via a gold nanocluster\/lipid core-shell nanocarrier","volume":"4","author":"Wang","year":"2017","journal-title":"Adv. Sci."},{"issue":"46","key":"10.1016\/j.biomaterials.2022.121876_bib192","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.201703036","article-title":"Targeted delivery of CRISPR\/Cas9-Mediated cancer gene therapy via liposome-templated hydrogel nanoparticles","volume":"27","author":"Chen","year":"2017","journal-title":"Adv. Funct. Mater."},{"issue":"4","key":"10.1016\/j.biomaterials.2022.121876_bib193","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav7199","article-title":"Near-infrared upconversion-activated CRISPR-Cas9 system: a remote-controlled gene editing platform","volume":"5","author":"Pan","year":"2019","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121876_bib194","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1073\/pnas.1912220117","article-title":"Near-infrared optogenetic engineering of photothermal nanoCRISPR for programmable genome editing","volume":"117","author":"Chen","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"47","key":"10.1016\/j.biomaterials.2022.121876_bib195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib196","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acsnano.6b04261","article-title":"Artificial virus delivers CRISPR-cas9 system for genome editing of cells in mice","volume":"11","author":"Li","year":"2017","journal-title":"ACS Nano"},{"issue":"45","key":"10.1016\/j.biomaterials.2022.121876_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202104641","article-title":"Sono-controllable and ROS-sensitive CRISPR-cas9 genome editing for augmented\/synergistic ultrasound tumor nanotherapy","volume":"33","author":"Pu","year":"2021","journal-title":"Adv. Mater."},{"issue":"37","key":"10.1016\/j.biomaterials.2022.121876_bib198","doi-asserted-by":"crossref","first-page":"18295","DOI":"10.1073\/pnas.1904697116","article-title":"Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel","volume":"116","author":"Guo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121876_bib199","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1021\/acs.nanolett.9b02501","article-title":"NanoRNP overcomes tumor heterogeneity in cancer treatment","volume":"19","author":"Liu","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.biomaterials.2022.121876_bib200","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jconrel.2019.05.019","article-title":"Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR\/Cas9 system suppressed the metastasis of pancreatic cancer","volume":"304","author":"Li","year":"2019","journal-title":"J. Contr. Release"},{"issue":"29","key":"10.1016\/j.biomaterials.2022.121876_bib201","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4005","article-title":"Codelivery of CRISPR-Cas9 and chlorin e6 for spatially controlled tumor-specific gene editing with synergistic drug effects","volume":"6","author":"Deng","year":"2020","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib202","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1039\/C8BM00263K","article-title":"Systemic delivery of CRISPR\/Cas9 with PEG-PLGA nanoparticles for chronic myeloid leukemia targeted therapy","volume":"6","author":"Liu","year":"2018","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2022.121876_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120275","article-title":"Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR\/Cas9-based cancer immunotherapy","volume":"258","author":"Liu","year":"2020","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib204","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib205","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib206","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2022.121876_bib207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","journal-title":"BoneKEy Rep."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib208","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1039\/C7BM00271H","article-title":"Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease","volume":"5","author":"Wang","year":"2017","journal-title":"Biomater. Sci."},{"issue":"35","key":"10.1016\/j.biomaterials.2022.121876_bib209","doi-asserted-by":"crossref","first-page":"14957","DOI":"10.1002\/anie.202004994","article-title":"Protein and mRNA delivery enabled by cholesteryl-based biodegradable lipidoid nanoparticles","volume":"59","author":"Li","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"45","key":"10.1016\/j.biomaterials.2022.121876_bib210","doi-asserted-by":"crossref","first-page":"20083","DOI":"10.1002\/anie.202008082","article-title":"Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes","volume":"59","author":"Zhao","year":"2020","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biomaterials.2022.121876_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114087","article-title":"CRISPR\/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells","volume":"181","author":"Bloomer","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib212","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf4398","article-title":"Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver","volume":"7","author":"Kim","year":"2021","journal-title":"Sci. Adv."},{"issue":"25","key":"10.1016\/j.biomaterials.2022.121876_bib213","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf7820","article-title":"Genetically engineered cell membrane\u2013coated nanoparticles for targeted delivery of dexamethasone to inflamed lungs","volume":"7","author":"Park","year":"2021","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121876_bib214","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.ymthe.2018.05.014","article-title":"Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis","volume":"26","author":"Robinson","year":"2018","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib215","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib216","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib217","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-target effects in CRISPR\/Cas9-mediated genome engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121876_bib218","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving CRISPR-Cas nuclease specificity using truncated guide RNAs","volume":"32","author":"Fu","year":"2014","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib219","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/nar\/gkx1199","article-title":"Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs","volume":"46","author":"Ryan","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib220","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/hum.2015.084","article-title":"Dimeric CRISPR RNA-guided FokI-dCas9 nucleases directed by truncated gRNAs for highly specific genome editing","volume":"26","author":"Wyvekens","year":"2015","journal-title":"Hum. Gene Ther."},{"issue":"7676","key":"10.1016\/j.biomaterials.2022.121876_bib221","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature24268","article-title":"Enhanced proofreading governs CRISPR-Cas9 targeting accuracy","volume":"550","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib222","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1038\/s41467-018-05477-x","article-title":"Directed evolution of CRISPR-Cas9 to increase its specificity","volume":"9","author":"Lee","year":"2018","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib223","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3390\/cells9071608","article-title":"Latest developed strategies to minimize the off-target effects in CRISPR-cas-mediated genome editing","volume":"9","author":"Naeem","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biomaterials.2022.121876_bib224","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.895713","article-title":"Viral vectors for the in vivo delivery of CRISPR components: advances and challenges","volume":"10","author":"Asmamaw Mengstie","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121876_bib225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/biot.201400529","article-title":"CRISPR genome engineering and viral gene delivery: a case of mutual attraction","volume":"10","author":"Schmidt","year":"2015","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.biomaterials.2022.121876_bib226","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.omtn.2018.12.008","article-title":"Viral vector-based delivery of CRISPR\/Cas9 and donor DNA for homology-directed repair in an in vitro model for canine hemophilia B","volume":"14","author":"Gao","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib227","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/acs.molpharmaceut.1c00916","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Kazemian","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2022.121876_bib228","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jconrel.2022.08.042","article-title":"LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea","volume":"350","author":"Mirjalili Mohanna","year":"2022","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2022.121876_bib229","first-page":"1","article-title":"Lipid-based nanocarrier mediated CRISPR\/Cas9 delivery for cancer therapy","author":"Aziz","year":"2022","journal-title":"J. Biomater. Sci. Polym. Ed."},{"issue":"16","key":"10.1016\/j.biomaterials.2022.121876_bib230","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8011","article-title":"Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy","volume":"8","author":"Zou","year":"2022","journal-title":"Sci. Adv."},{"issue":"3\u20134","key":"10.1016\/j.biomaterials.2022.121876_bib231","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-021-00282-6","article-title":"Non-viral delivery of CRISPR-Cas9 complexes for targeted gene editing via a polymer delivery system","volume":"29","author":"O'Keeffe Ahern","year":"2022","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121876_bib232","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071495","article-title":"Nanodevices for the efficient codelivery of CRISPR-cas9 editing machinery and an entrapped cargo: a proposal for dual anti-inflammatory therapy","volume":"14","author":"Garcia-Fernandez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biomaterials.2022.121876_bib233","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.957572","article-title":"Nanocarriers: a novel strategy for the delivery of CRISPR\/Cas systems","volume":"10","author":"Hejabi","year":"2022","journal-title":"Front. Chem."},{"issue":"9","key":"10.1016\/j.biomaterials.2022.121876_bib234","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3390\/pharmaceutics14091842","article-title":"Non-viral delivery of CRISPR\/cas cargo to the retina using nanoparticles: current possibilities, challenges, and limitations","volume":"14","author":"Salman","year":"2022","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121876_bib235","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1039\/D1CC05999H","article-title":"Nanoparticle-based non-viral CRISPR delivery for enhanced immunotherapy","volume":"58","author":"Shin","year":"2022","journal-title":"Chem. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib236","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12915-018-0624-2","article-title":"In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model","volume":"17","author":"Carreras","year":"2019","journal-title":"BMC Biol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121876_bib237","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR technologies for precise epigenome editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.biomaterials.2022.121876_bib238","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/305716","article-title":"Efficient mitochondrial genome editing by CRISPR\/Cas9","volume":"2015","author":"Jo","year":"2015","journal-title":"BioMed Res. Int."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121876_bib239","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41584-018-0001-0","article-title":"Mitochondrial DNA variation and the pathogenesis of osteoarthritis phenotypes","volume":"14","author":"Blanco","year":"2018","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222005166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222005166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:13:35Z","timestamp":1758906815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961222005166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":239,"alternative-id":["S0142961222005166"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121876","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121876"}}